SYDNEY BEAVERS: Open Payments
NPI 1467108902 · PLANO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$784 in 38 payments from 19 companies in 2025. Trend: 2023 $19 · 2024 $0 · 2025 $784
Food & beverage: $784
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $148 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $92 |
| ABBVIE INC. | 3 | $78 |
| Lilly USA, LLC | 4 | $56 |
| Astellas Pharma US Inc | 3 | $52 |
| Azurity Pharmaceuticals, Inc. | 3 | $51 |
| GlaxoSmithKline, LLC. | 3 | $49 |
| Dexcom, Inc. | 2 | $42 |
| Janssen Pharmaceuticals, Inc | 2 | $36 |
| Novo Nordisk Inc | 1 | $30 |
Products named: Kerendia, QULIPTA, Veozah, AZMIRO, MOUNJARO, Dexcom G6 Transmitter, SPRAVATO, SHINGRIX.
Industry payments across TX — which companies pay providers there.
